NCT04594135

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: iCell Gene Therapeutics · Industry
• Sex: All
• Age: 8 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD5 CART cells in patients with relapsed and/or refractory T cell lymphoma or leukemia.

Detailed description

Anti- CAR is a chimeric antigen receptor immunotherapy treatment designed to treat lymphoma/leukemia expressing CD5 antigen. CD5+ T cell lymphomas or leukemia are a subset of leukemias and lymphomas that are positive for the surface protein CD5. The purpose of this study is to evaluate the efficacy and safety of anti-CD5 CAR T cells.

Conditions

• T-cell Acute Lymphoblastic Leukemia
• T-cell Non-Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	anti-CD5 CAR T cells	anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells

Timeline

• Start date: 2020-12-01
• Primary completion: 2023-11-30
• Completion: 2023-11-30
• First posted: 2020-10-20
• Last updated: 2021-03-02

Locations

1 site across 1 country: China